BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27307596)

  • 21. Quantification and phenotypic characterization of peripheral blood Vδ1 + T cells in chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Simões C; Silva I; Carvalho A; Silva S; Santos S; Marques G; Ribeiro A; Roque A; Carda J; Sarmento-Ribeiro AB; Domingues MDR; Ribeiro L; Paiva A
    Cytometry B Clin Cytom; 2019 Mar; 96(2):164-168. PubMed ID: 30334339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
    Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
    J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Large scale expansion of Vgamma9Vdelta2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS "TCR gamma/delta+ T cell isolation kit".
    Salot S; Bercegeay S; Dreno B; Saïagh S; Scaglione V; Bonnafous C; Sicard H
    J Immunol Methods; 2009 Aug; 347(1-2):12-8. PubMed ID: 19465023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
    Beck BH; Kim HG; Kim H; Samuel S; Liu Z; Shrestha R; Haines H; Zinn K; Lopez RD
    Breast Cancer Res Treat; 2010 Jul; 122(1):135-44. PubMed ID: 19763820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
    Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE
    Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera.
    Shimoni A; Marcus H; Dekel B; Shkarchi R; Arditti F; Shvidel L; Shtalrid M; Bucher W; Canaan A; Ergas D; Berrebi A; Reisner Y
    Cancer Res; 1999 Dec; 59(23):5968-74. PubMed ID: 10606243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.
    Coscia M; Vitale C; Peola S; Foglietta M; Rigoni M; Griggio V; Castella B; Angelini D; Chiaretti S; Riganti C; Guarini A; Drandi D; Ladetto M; Bosia A; Foà R; Battistini L; Boccadoro M; Fournié JJ; Massaia M
    Blood; 2012 Oct; 120(16):3271-9. PubMed ID: 22932792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
    Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Mysterious Actor-γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL).
    Zarobkiewicz MK; Bojarska-Junak AA
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
    Fraietta JA; Schwab RD; Maus MV
    Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.
    Oldreive CE; Skowronska A; Davies NJ; Parry H; Agathanggelou A; Krysov S; Packham G; Rudzki Z; Cronin L; Vrzalikova K; Murray P; Odintsova E; Pratt G; Taylor AM; Moss P; Stankovic T
    Dis Model Mech; 2015 Nov; 8(11):1401-12. PubMed ID: 26398941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
    Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
    Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
    [No Abstract]   [Full Text] [Related]  

  • 36. Increased frequencies of circulating and tumor-resident Vδ1
    Reboursiere E; Gac AC; Garnier A; Salaun V; Reman O; Pham AD; Cabrera Q; Khoy K; Vilque JP; Fruchart C; Chantepie S; Johnson-Ansah H; Macro M; Cheze S; Benabed K; Mear JB; Troussard X; Damaj G; Le Mauff B; Toutirais O
    Leuk Lymphoma; 2018 Jan; 59(1):187-195. PubMed ID: 28562153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.
    Sandri S; Bobisse S; Moxley K; Lamolinara A; De Sanctis F; Boschi F; Sbarbati A; Fracasso G; Ferrarini G; Hendriks RW; Cavallini C; Scupoli MT; Sartoris S; Iezzi M; Nishimura MI; Bronte V; Ugel S
    Cancer Res; 2016 May; 76(9):2540-51. PubMed ID: 27197263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
    Chen J; Niu H; He W; Ba D
    Int Arch Allergy Immunol; 2001 Jul; 125(3):256-63. PubMed ID: 11490159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.